Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2006

View Archived Issues

Low blood and tumor tissue levels of tasquinimod sufficient for antiangiogenic actions

M.D. Anderson and Baylor team up in asthma and allergic diseases

Preclinical and clinical antiplatelet efficacy of pasugrel demonstrated

Sativex and placebo show similar significant efficacy in patients with painful diabetic neuropathy

Safety and efficacy of SB-509 demonstrated in a phase I trial in patients with diabetic neuropathy

SGLT-2 inhibitor AVE-2268 effectively lowers blood glucose and urinary glucose excretion in rodents

KW-3902 improves diuresis and renal function in patients with heart failure and renal impairment

Analgesic properties of the anticancer agent BIM-46187

Analgesic potential for PAR4 agonists

Santen patents novel strategy for allergic conjunctivitis

Recent patents impart new therapeutic agents for cancer

Recent patents divulge novel analgesic agents

Serono and Syntonix establish agreement to develop uniquely delivered FSH infertility treatment

Phase II trial under way with ASF-1096 for discoid lupus erythematosus

Cell Therapeutics establishes global alliance with Novartis for Xyotax

Clavis Pharma and Mount Sinai School of Medicine to collaborate on anticancer drugs

ArmaGen receives grant to develop first nerve gas antidote

Schering AG grants Bausch & Lomb license to SEGRA for ophthalmic use

Pfizer and Trans Tech Pharma to develop RAGE products for Alzheimer's disease

Milestone payment to AnorMED for Fosrenol approval in Germany

E.U. orphan medicinal product designation assigned to Nektar's amphotericin B inhalation powder

Opexa Therapeutics provides update on preclinical and clinical progress

ExonHit Therapeutics and Allergan strengthen strategic alliance

Organon and Schering AG to discontinue codevelopment of male hormonal contraceptive

Aastrom Biosciences reports promising interim data for Tissue Repair Cells

The VEGF antagonist bevacizumab shows promise in HHT: News in Context

Selective norepinephrine reuptake inhibitors developed by Wyeth

Connetics' Verdeso Foam approved for atopic dermatitis indication in U.S.

GlaxoSmithKline seeks FDA approval for Tykerb for advanced breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...